Get notified when INO files again. Create a free account and we'll email you the moment its next filing is analyzed.
Get filing alertsRed Flags Detected
- Going Concern (new) — The company explicitly states substantial doubt about its ability to continue as a going concern, a serious financial viability warning.
- Fda Accelerated Approval Uncertainty (new) — The FDA noted a preliminary conclusion that the company had not provided adequate information to justify eligibility for the accelerated approval pathway for INO-3107.
- Competitive Threat From Papzimeos (new) — A competing product, PAPZIMEOS, has already received traditional approval for RRP, which could limit the market opportunity for INO-3107.
- Dilution / Overhang (new) — New investors face immediate dilution of $0.91 per share, and the company has an active ATM program with $56.8M remaining capacity.
INOVIO prices $17.5M primary offering of 12.5M shares with warrants at $1.40 per unit
Filed April 2, 2026 · ~1 min read
Key Changes
-
high
INOVIO is offering 12.5M shares with Series A and B warrants at $1.40 per unit, raising $17.5M gross and $16M net for the company.
The Offering verify on EDGAR → -
high
The company has no product revenue and states substantial doubt exists about its ability to continue as a going concern.
Prospectus Summary verify on EDGAR → -
high
Net proceeds will fund INO-3107 launch prep, a confirmatory trial, pipeline development, and general corporate purposes.
Use of Proceeds verify on EDGAR →
3 more material changes behind this preview — plus the full narrative summary, section-by-section diffs against the prior filing, and verbatim quotes with EDGAR citations.
Want to see a complete report first? Today's free report (WLTH 10-Q) is open in full — no account needed.
Partner
Trade INO commission-free
Open an account, get a free stock.
Investing involves risk. Free stock terms apply.
Thanks — your feedback helps us improve report quality.
Figures/quotes linked to EDGAR · Narrative written by AI · Sep 2, 2026 · How we verify